KM Research Hub
← 返回论文库
待处理 入排:待复核 图源:待检查 入排置信度 0.45

RATIONALE 311: tislelizumab plus concurrent chemoradiotherapy for localized esophageal squamous cell carcinoma.

Rong Yu, Wenqing Wang, Tao Li, Jiancheng Li, Kuaile Zhao, Weihu Wang, Long Liang, Haishan Wu, Tashan Ai, Wei Huang, Liyun Li, Wentao Yu, Chenlu Wei, Yidi Wang, Wei Shen, Zefen Xiao

Future Oncol 17(31) 4081-4089

PMID34269067
PMCID-
DOI10.2217/fon-2021-0632
发表日期2021-07-16
入排依据:The record describes a Phase III, randomized, drug-intervention trial in esophageal cancer, meeting core oncology, human, randomization, and phase criteria. However, the title and abstract do not explicitly report results for a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS) nor present Kaplan-Meier curves or hazard ratios. The document is identified as a protocol/rationale ('study described here'), not a formal result report. Therefore, is_eligible is set to null due to insufficient evidence for the time_to_event and original_result criteria.
摘要

摘要

Definitive chemoradiotherapy is the standard of care for inoperable locoregionally advanced esophageal squamous cell carcinoma (ESCC). Immune checkpoint inhibitors such as anti-PD-1/PD-L1 antibodies have led to a paradigm shift in advanced, metastatic ESCC treatment; however, the effect of incorporating checkpoint inhibitors in the definitive management of ESCC is unclear. Tislelizumab is an anti-PD-1 antibody specifically engineered to minimize FcɣR binding on macrophages to abrogate antibody-dependent phagocytosis, a mechanism of T-cell clearance and potential resistance to anti-PD-1 therapy. The RATIONALE 311 study described here (BGB-A317-311; NCT03957590) is a registrational multicenter, double-blind, placebo-controlled, randomized, Phase III clinical trial designed to evaluate the efficacy and safety of tislelizumab combined with concurrent chemoradiotherapy in patients with inoperable localized ESCC.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。